Semaglutide in South Africa — A 2025 Guide for South Africans

You have almost certainly heard about Ozempic. Possibly Wegovy. You may have seen people talking about dramatic weight loss results, or heard debate about whether it is safe, whether it works long-term, or whether it is "cheating." South African interest in semaglutide has exploded over the past two years, and the questions coming through on WhatsApp and search engines reflect a population that is genuinely trying to understand this compound — not just chase a trend.

This guide cuts through the noise. What semaglutide actually is, what the evidence shows, what access looks like in South Africa in 2025, and what questions to ask before you consider it.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a compound that mimics and amplifies the action of glucagon-like peptide 1 (GLP-1), a hormone naturally produced in your gut after eating.

GLP-1 has several roles in metabolic regulation. It stimulates insulin secretion in response to food, suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying and — crucially — acts on the brain's appetite and reward centres to reduce hunger and increase satiety.

Semaglutide was originally developed for type 2 diabetes management, where it proved effective at lowering blood glucose and HbA1c. The weight loss effect was noticed in clinical trials and subsequently studied in dedicated obesity trials. The results were striking enough to change the conversation around obesity medicine globally.

What Does the Evidence Show?

The STEP trial programme — a series of large, randomised, placebo-controlled trials — established semaglutide's efficacy for weight loss with unusually robust evidence.

In STEP 1, adults with obesity or overweight (plus at least one weight-related condition) receiving weekly subcutaneous semaglutide at 2.4mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. That is a level of weight loss previously only achievable through bariatric surgery.

STEP 5 showed that this effect was maintained over two years. STEP 4 demonstrated that stopping semaglutide results in weight regain — underscoring that it works as long as it is used, not as a cure that persists after discontinuation.

Secondary outcomes across the STEP trials included improvements in blood pressure, lipid profiles, inflammatory markers and quality of life measures.

What South Africans Are Actually Asking

The questions we hear most often:

Is Ozempic available in South Africa?
Yes. Ozempic (the diabetes-approved formulation at 0.5mg and 1mg) is registered in South Africa and available through prescription via a doctor. Wegovy (the higher-dose 2.4mg formulation specifically approved for obesity) has been approved internationally but its availability through the South African pharmacy network is more limited. Consult your GP or an endocrinologist about the current position.

Can I get semaglutide without a prescription in South Africa?
Pharmaceutical semaglutide — Ozempic or Wegovy — requires a prescription. It is a registered medicine. Research-grade semaglutide from peptide suppliers occupies a different category and is sold without a prescription as a research compound. This is an important distinction. If you are managing a medical condition, the pharmaceutical route through a healthcare provider is the appropriate path.

Is it safe to use long-term?
The trial data extends to two years with a favourable safety profile for most users. The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea — and are most pronounced during the dose escalation phase. Rare but serious concerns include pancreatitis and thyroid C-cell effects (the latter was observed in rodent models and is a contraindication in people with certain thyroid conditions or family history of medullary thyroid carcinoma).

What happens when you stop?
Weight regain is expected. This is one of the most important things to understand. Semaglutide is not a short course that resets your metabolism. It works as long as you use it. Sustainable lifestyle habits built alongside semaglutide therapy are what determine long-term outcomes.

The Cost Reality in South Africa

Cost is a genuine barrier for many South Africans. Branded Ozempic through a pharmacy can run to several thousand rand per month depending on dose. Medical aid coverage varies significantly — some schemes cover it for diabetes management, very few cover it for obesity specifically.

This cost gap is part of why research-grade semaglutide has found an audience in South Africa. For those who understand the distinction between pharmaceutical and research-grade product and are making an informed, adult decision, it represents a more accessible option.

If cost is a concern and you are exploring options, speaking to a pharmacist or GP about what your medical aid covers — and whether compounding pharmacy options exist — is worth doing.

What to Consider Before Starting

Semaglutide is not for everyone. It is not a lifestyle shortcut and it is not without side effects.

Think about it seriously if:
- You have obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related health condition
- You have tried lifestyle modification seriously and not achieved meaningful results
- You are prepared for the dose escalation phase (8–20 weeks) during which side effects are most common
- You understand that discontinuation will likely result in weight regain

Think carefully — or speak to a doctor first — if:
- You have a personal or family history of medullary thyroid carcinoma or MEN2
- You have a history of pancreatitis
- You are pregnant or planning pregnancy
- You are already on diabetes medication and would need to adjust your regimen

We are not a medical provider, and nothing in this article is medical advice. But we are happy to have an honest conversation about what options look like for your situation — reach us on WhatsApp any time.

The Bottom Line

Semaglutide is the most evidence-backed weight loss intervention available outside of bariatric surgery. The results in trials are real and meaningful. The access landscape in South Africa is evolving, with pharmaceutical options available through prescription and research-grade options available through suppliers. Understanding the difference, knowing what to look for in terms of quality, and making a decision that suits your health situation is what matters most.